Difference between revisions of "Benralizumab (Fasenra)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
|||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
''No approval for hematology/oncology conditions, at this time.'' | ''No approval for hematology/oncology conditions, at this time.'' | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf Benralizumab (Fasenra) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf Benralizumab (Fasenra) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Fasenra | *'''Brand names:''' Fasenra | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 10:07, 4 April 2021
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
History of changes in FDA indication
No approval for hematology/oncology conditions, at this time.
Patient Drug Information
Also known as
- Brand names: Fasenra